Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT semaglutide cardiovascular outcomes trial in overweight or obese adults with established cardiovascular disease
MOH_2018-07-16_002482Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in Overweight, obesity and cardiac morbidity comparing Semaglutide with Placebo (2 arms). Started Jun 2018; status: completed.
02
Drugs
03
Conditions
Overweightobesitycardiac morbidity
Beyond the preview
Go deeper on MOH_2018-07-16_002482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-16_002482.